Marko Velimirovic, MD

Articles by Marko Velimirovic, MD

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

ByMarko Velimirovic, MD,Aditya Bardia, MD, MPH, FASCO

March 12th 2019

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

Latest Updated Articles

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer
March 12th 2019

Marko Velimirovic, MD

Articles by Marko Velimirovic, MD

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

Latest Updated Articles

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026

Meta-Analysis Shows Ropeginterferon Alfa-2b Benefit Over Phlebotomy, but Not Hydroxyurea, in Polycythemia Vera